Finch Therapeutics Group, Inc. Announces Board Changes
April 27, 2021 at 07:17 am EDT
Share
On April 23, 2021, the Board of Directors of Finch Therapeutics, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased the size of the Board from seven members to eight members and elected Susan Graf to its Board, effective immediately, to serve as a Class II director whose term will expire at the Company’s 2023 Annual Meeting of Stockholders. On April 23, 2021, Ms. Graf was also appointed to serve as the chairperson of the Audit Committee of the Board. Dominic Ferrante, the prior chairperson of the Audit Committee, will continue to serve as a member of the Audit Committee. In connection with Ms. Graf’s appointment to the Audit Committee, Nicholas Haft resigned as a member of the Audit Committee. Mr. Haft will continue as a member of the Board.
Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 113 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. Its assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohnâs disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.